Skip to main content
Darzalex Faspro 1800 mg/15mL, 30000 U/15mL injection by Janssen Biotech, Inc.
Darzalex Faspro, 1800 mg/15mL, 30000 U/15mL, injection Drug class: CD38-directed Cytolytic Antibody; Endoglycosidase. Available on prescription only. Listed by Janssen Biotech, Inc..
Prescription only

Darzalex Faspro

daratumumab and hyaluronidase-fihj (human recombinant)

Listed by Janssen Biotech, Inc.

Strength
1800 mg/15mL, 30000 U/15mL
Form
Injection
Route
Subcutaneous
Class
CD38-directed Cytolytic Antibody; Endoglycosi…

What it contains

  • Daratumumab 1800 mg/15mL
  • Hyaluronidase (human Recombinant) 30000 U/15mL

This is a combination product. It is not interchangeable with a single-ingredient medicine containing only one of these.

FDA record

Dosage form Injection
Route Subcutaneous
Drug class CD38-directed Cytolytic Antibody; Endoglycosidase
Approval route BLA — biologic licence
NDC code 57894-503
FDA application BLA761145
RxNorm concept 2375136
Package sizes listed 1
Marketed since May 2020

Other products containing Daratumumab

See all

Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.

DARZALEX

Daratumumab

Strength
100 mg/5mL
Form
Injection, Solution, Concentrate
Class
CD38-directed Cytolytic Antibody
Rx only

Janssen Biotech, Inc.

Not stocked by us — reference only

Darzalex IV

Daratumumab

Strength
100 mg/5mL
Form
Injection, Solution, Concentrate
Class
CD38-directed Cytolytic Antibody
Rx only

Janssen Biotech, Inc.

Not stocked by us — reference only

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.